Rhumbline Advisers boosted its position in Radius Health, Inc. (NASDAQ:RDUS) by 9.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 42,480 shares of the biopharmaceutical company’s stock after buying an additional 3,740 shares during the period. Rhumbline Advisers owned approximately 0.10% of Radius Health worth $1,921,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. acquired a new position in Radius Health in the first quarter valued at $105,000. Sei Investments Co. increased its stake in Radius Health by 27.7% in the second quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 690 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in Radius Health by 1.1% in the first quarter. Envestnet Asset Management Inc. now owns 4,231 shares of the biopharmaceutical company’s stock valued at $163,000 after purchasing an additional 46 shares in the last quarter. Karp Capital Management Corp bought a new stake in Radius Health in the first quarter valued at $217,000. Finally, Oppenheimer Asset Management Inc. bought a new stake in Radius Health in the first quarter valued at $228,000.

Shares of Radius Health, Inc. (RDUS) opened at 33.54 on Friday. Radius Health, Inc. has a 1-year low of $31.58 and a 1-year high of $59.22. The firm has a 50-day moving average of $37.32 and a 200 day moving average of $39.12. The company’s market capitalization is $1.46 billion.

Radius Health (NASDAQ:RDUS) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.35) by ($0.23). The firm had revenue of $0.98 million for the quarter, compared to analysts’ expectations of $1.96 million. During the same period last year, the company posted ($1.01) earnings per share. On average, equities research analysts expect that Radius Health, Inc. will post ($5.58) earnings per share for the current year.

Several equities research analysts have weighed in on RDUS shares. Jefferies Group LLC set a $34.00 price target on shares of Radius Health and gave the company a “hold” rating in a research note on Monday, June 5th. ValuEngine raised shares of Radius Health from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. BidaskClub raised shares of Radius Health from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. Zacks Investment Research raised shares of Radius Health from a “sell” rating to a “hold” rating in a research note on Tuesday, August 8th. Finally, Cantor Fitzgerald set a $65.00 price target on shares of Radius Health and gave the company a “buy” rating in a research note on Monday, May 22nd. Two analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $53.60.

In related news, CFO Jose Carmona bought 3,000 shares of the company’s stock in a transaction dated Thursday, September 14th. The stock was purchased at an average cost of $32.83 per share, with a total value of $98,490.00. Following the transaction, the chief financial officer now owns 3,000 shares in the company, valued at approximately $98,490. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Growth N. V. Biotech bought 150,000 shares of the company’s stock in a transaction dated Thursday, August 10th. The stock was bought at an average cost of $34.97 per share, with a total value of $5,245,500.00. Following the completion of the transaction, the insider now owns 5,113,799 shares in the company, valued at approximately $178,829,551.03. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 469,100 shares of company stock valued at $16,328,382. Corporate insiders own 15.00% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Radius Health, Inc. (RDUS) Position Boosted by Rhumbline Advisers” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.thecerbatgem.com/2017/09/17/radius-health-inc-rdus-position-boosted-by-rhumbline-advisers.html.

Radius Health Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Institutional Ownership by Quarter for Radius Health (NASDAQ:RDUS)

Receive News & Stock Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related stocks with our FREE daily email newsletter.